Law360, New York (January 26, 2009, 12:00 AM ET) -- The U.S. Food and Drug Administration has announced it is working with Sanofi-Aventis SA and Bristol-Myers Squibb Co. to examine the impact of other drugs and genetic factors on the effectiveness of the drug giants' blockbuster blood thinner Plavix.
The two makers of clopidogrel, which is co-marketed as Plavix, have agreed to work with the FDA to conduct studies to gain a better understanding of those effects, the FDA said Monday.
The announcement follows published studies that suggest that clopidogrel, an antiplatelet that is used to...
FDA, Drug Cos. To Review Blood Thinner Plavix
To view the full article, take a free trial now.
